Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC and BCM Families Foundation Announce Collaboration to Develop AAV-Based Gene Therapy for Blue Cone Monochromacy
GAINESVILLE, Fla. and JUPITER, Fla. and CAMBRIDGE, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases,
View HTML
Toggle Summary AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness
Innovative approach will combine AGTC's gene therapy expertise with Bionic Sight's neuro-prosthetic device to potentially restore retinal function
View HTML
Toggle Summary AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Results expected to enhance development of AGTC's XLRS gene therapy candidate; Phase 1/2 clinical trial currently enrolling patients at multiple locations across the United States
View HTML
Toggle Summary AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
Toggle Summary AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
AGTC Grant Will Support FFB's Patient Registry and Local Programs
View HTML
Toggle Summary AGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated Achromatopsia
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical College
View HTML
Toggle Summary AGTC and the Medical College of Wisconsin Announce Publication of Natural History Study Data Evaluating Residual Photoreceptor Cone Status in Patients with CNGB3-associated Achromatopsia
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical
View HTML
Toggle Summary AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board
GAINESVILLE, Fla. , and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating
View HTML
Toggle Summary AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials Webcast Scheduled from 7:30 am – 12:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
View HTML
Visionary science for life changing cures.